Dynamic cellular phenotyping defines specific mobilization mechanisms of human hematopoietic stem and progenitor cells induced by SDF1α versus synthetic agents
Sign Up to like & getrecommendations! Published in 2018 at "Scientific Reports"
DOI: 10.1038/s41598-018-19557-x
Abstract: Efficient mobilization of hematopoietic stem and progenitor cells (HSPC) is one of the most crucial issues for harvesting an adequate amount of peripheral HSPC for successful clinical transplantation. Applying well-defined surrogate models for the bone… read more here.
Keywords: progenitor cells; stem progenitor; mobilization; hematopoietic stem ... See more keywords
Phase I/II study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz246.090
Abstract: Abstract Background NOX-A12 is an inhibitor of the chemokine CXCL12 which prevents receptor engagement and blocks the formation of chemotactic CXCL12 concentration gradients. The Opera study (NCT03168139) is a Phase 1/2 study to evaluate pharmacodynamic… read more here.
Keywords: phase; time; study; noxxon pharma ... See more keywords
Abstract CT092: Clinical outcome and safety in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 in combination with PD-1 checkpoint inhibitor pembrolizumab
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2019-ct092
Abstract: BACKGROUND. NOX-A12 is an inhibitor of the chemokine CXCL12 for treatment of solid tumors. Binding of CXCL12 by NOX-A12 prevents receptor engagement and blocks the ability of CXCL12 to form a chemotactic concentration gradient. The… read more here.
Keywords: pembrolizumab; treatment; cancer; nox a12 ... See more keywords
Evaluation of tumor biomarkers in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 and preliminary safety in combination with PD-1 checkpoint inhibitor pembrolizumab.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e15094
Abstract: e15094Background: NOX-A12 (olaptesed pegol) is a novel inhibitor of the chemokine CXCL12 for treatment of solid tumors. The Opera study (NCT03168139) is a Phase 1/2 open label clinical study to evaluate pharmacodynamic effects and safety… read more here.
Keywords: combination; metastatic colorectal; inhibitor; safety ... See more keywords